Premium
Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa
Author(s) -
Ferreira Jaderson V.,
Chaves Gisele A.,
Marino Bianca L. B.,
Sousa Kessia P. A.,
Souza Lucilene R.,
Brito Maiara F. B.,
Teixeira Hueldem R. C.,
da Silva Carlos H. T. P.,
Santos Cleydson B. R.,
HageMelim Lorane I. S.
Publication year - 2017
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201700129
Subject(s) - cannabinoid receptor , cannabinoid , cannabis sativa , cannabis dependence , endocannabinoid system , pharmacology , drug , receptor , chemistry , medicine , cannabis , bioinformatics , biology , psychiatry , biochemistry , antagonist , botany , cannabidiol
Cannabis sativa withdrawal syndrome is characterized mainly by psychological symptoms. By using computational tools, the aim of this study was to propose drug candidates for treating withdrawal syndrome based on the natural ligands of the cannabinoid type 1 receptor (CB1). One compound in particular, 2‐ n ‐butyl‐5‐ n ‐pentylbenzene‐1,3‐diol (ZINC1730183, also known as stemphol), showed positive predictions as a human CB1 ligand and for facile synthetic accessibility. Therefore, ZINC1730183 is a favorable candidate scaffold for further research into pharmacotherapeutic alternatives to treat C. sativa withdrawal syndrome.